摘要
目的:评价阿托伐他汀、西地那非、阿托伐他汀和西地那非联合治疗肺动脉高压(PAH)的临床疗效。方法:选择45例PAH患者为研究对象。随机分为3组,每组15例,分别给予阿托伐他汀(阿托伐他汀组)、西地那非(西地那非组)、阿托伐他汀和西地那非联合(联合药物组)治疗,治疗前及治疗后6个月进行右心导管检查及6 min步行距离(6MWT)检测治疗效果。结果:3组治疗均能降低PAH患者肺血管阻力(P<0.05),西地那非组及联合药物组可以降低肺动脉压力(P<0.05),提高心脏指数(P<0.05),增加6MWT,其中联合2种药物较之单一用药更能降低肺动脉压力(P<0.05),增加6MWT(P<0.05),疗效进一步增强。结论:阿托伐他汀联合西地那非能有效治疗PAH患者,是一种相对经济有效的治疗方法。
Objective：To evaluate the clinical effects of treatment with atorvastatin,sildenafil and their combination on pulmonary arterial hypertension（PAH）.Method：From October 2007 to June 2010,45 patients diagnosed with PAH were randomized to atorvastatin（10 mg QN）,sildenafil（50 mg BID） and a combination of atorvastatin and sildenafil（n=15,respectively）.Six months later,hemodynamic study and 6-minute walking test were measured.Result： Compared to baseline,Pulmonary vascular resistance（PVR） was significantly decreased in monotherapy groups（atorvastatin or sildenafil） and the combination group（P0.05）.Compared to baseline,mean pulmonary artery pressure（mPAP） was significantly decreased in sildenafil group and the combination group（P0.05）.Compared to baseline,Cardiac index（CI） and 6MWT were significantly improved in sildenafil group and the combination group（P0.05）.The combination therapy provided additive benefits through decreasing mPAP and improving 6MWT（P0.05）.Conclusion：The combination of aorvastatin and sildenafil was effective for patients with PAH.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2011年第5期352-354,共3页
Journal of Clinical Cardiology
基金
江西省教育厅科技计划(GJJ08139)
关键词
阿托伐他汀
肺动脉高压
西地那非
atorvastatin
pulmonary arterial hypertension
sildenafil
